Skip to main content

INDV 6-K

Indivior Pharmaceuticals, Inc. (INDV)

6-K 2024-10-22 For: 2024-10-22
View Original
Added on April 10, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

________________________

Washington, D.C. 20549

_____________________

FORM 6-K

_____________________

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October 2024

Commission File Number: 001-37835

________________________________________

Indivior PLC

________________________________________

10710 Midlothian Turnpike, Suite 125

North Chesterfield, Virginia 23235

(Address of principal executive office)

_______________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit<br>No. Description<br>of Exhibit
99.1 Announcement sent to the London Stock Exchange on October 22, 2024,<br>titled “Transaction in Own Shares”.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Indivior PLC
Date: October 22, 2024 /s/<br>Kathryn Hudson
Name:<br>Kathryn Hudson
Title:<br>Company Secretary

a2444j

Exhibit 99.1

INDIVIOR PLC

SHARE REPURCHASE PROGRAM

WEEKLY REPORT

October 22, 2024

INDIVIOR PLC ("Indivior") announces that it purchased for cancellation a total of 380,788 of its ordinary shares of $0.50 each through Morgan Stanley & Co. International Plc in the period from October 14, 2024, up to and including October 18, 2024, in connection with its $100m Share Repurchase Program. Aggregated information on the purchase of these shares can be found in the table below.

Following the purchase and cancellation of the above shares (including those purchased but not yet settled), Indivior has 128,207,710 ordinary shares of $0.50 each with voting rights in issue. There are no shares held in treasury.

The above figure (128,207,710) may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Indivior under the FCA's Disclosure Guidance and Transparency Rules.

All repurchases by Indivior are "On Exchange" transactions (as such term is defined in the rules of the London Stock Exchange) and "on market" for the purposes of the Companies Act 2006.

Aggregated information

Trading<br>Date Trading<br>Venue Aggregated<br>daily volume<br><br><br>(number<br>of shares) Daily<br>weighted average<br><br><br>purchase<br>price of the shares<br><br><br>(p)
14/10/2024 LSE 86,041 570.41
14/10/2024 BATE 25,891 571.56
14/10/2024 CHIX 48,103 564.91
14/10/2024 AQUIS 7,533 578.58
15/10/2024 LSE 37,125 589.43
15/10/2024 BATE 14,710 587.07
15/10/2024 CHIX 50,102 590.11
15/10/2024 AQUIS 5,580 594.58
16/10/2024 LSE 44,357 606.70
16/10/2024 BATE 15,651 607.14
16/10/2024 CHIX 40,627 609.40
16/10/2024 AQUIS 5,068 605.22

Transaction details

In accordance with Article 5(1)(b) of the assimilated Market Abuse Regulation (EU) No 596/2014, as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018 and Commission Delegated Regulation (EU) 2016/1052, a full breakdown of the individual purchases of ordinary shares made by Morgan Stanley & Co. International Plc on behalf of Indivior during the above period as part of the Share Repurchase Program can be found at www.indivior.com/en/investors/shareholder-information/share-repurchase-program.

Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.

Contact:

Jason Thompson

Vice President, Investor Relations

1-804-402-7123